Global Shake-up in Healthcare: Key Developments and Implications

Current health news highlights the FDA's approval of an injectable Opdivo, Anthem Biosciences' IPO plans, bird flu's resurgence in France, China's stance on COVID-19 data, a lawsuit on arsenic in baby food, and various drug developments including Novartis' gene therapy and Merck’s recently approved treatment.

The FDA has approved an injectable version of Bristol Myers Squibb's cancer drug Opdivo, marking a significant advancement in oncology treatment through PD-1 inhibitors that enhance the immune system. Meanwhile, Indian drugmaker Anthem Biosciences is set to launch a massive IPO, underscoring a hot trend in stock market listings.

France, having recently declared itself free of bird flu, faces new outbreaks in two poultry farms, a situation mirroring but less severe than the United States, where bird flu has affected both economy and health. In China, authorities defend their COVID-19 data-sharing practices amidst calls for increased transparency from the World Health Organization.

In legal news, Hain Celestial Group confronts a lawsuit over arsenic levels in baby foods, a case pivotal for consumer safety standards. Drug development remains dynamic with Novartis reporting progress on a gene therapy for spinal muscular atrophy, and UK approvals for Merck's new lung condition treatment.

(With inputs from agencies.)